Do not include Glucose 6 Phosphate Dehydrogenase (G6PD) in the tests required for Medically Assisted Reproduction (MAP)

Type of practice

Laboratory tests



Topic Area

Human Genetics

In the context of Medically Assisted Reproduction (MAP), especially in the absence of a positive family or personal history for the condition, testing for the G6PD enzyme should not be recommended. In the literature, in fact, there is no evidence to confirm that this deficit may explain infertility in couples. The available studies evaluating such associations are few, very dated, inconclusive and unconfirmed. It has also been confirmed that the G6PD deficit does not increase the susceptibility of sperm to oxidative stress. The role of G6PD in placental cells has been demonstrated in mouse models, but has not been confirmed in humans.
Good practice: Do not require G6PD testing every PMA pathway.


1. Longo L, Vanegas OC, Patel M, et al. Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO J. 2002 Aug 15;21(16):4229-39.
2. Roshankhah S, Rostami-Far Z, Shaveisi-Zadeh F, et al. Glucose-6-phosphate dehydrogenase deficiency does not increase the susceptibility of sperm to oxidative stress induced by H2O2. Clin Exp Reprod Med. 2016 Dec;43(4):193-198. doi: 10.5653/cerm.2016.43.4.193.
3. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014 Feb;164(4):469-80. doi: 10.1111/bjh.12665.



Attention. Please note that these items are provided only for information and are not intended as a substitute for consultation with a clinician. Patients with any specific questions about the items on this list or their individual situation should consult their clinician.